1. FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2020). Accessed. 03-19-2020: http://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-a....
2. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report;Wang KM;Kidney Med,2020
3. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program;Erondu N;Diabetes Care,2015
4. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant;Finucane FM;Med Hypotheses,2018
5. Euglycemic Diabetic Ketoacidosis;Plewa MC,2020